BioSpace News Archive

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, reported its financial results for the quarter ended March 31, 2020 and maintained its full year 2020 financial guidance.

Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, announced first quarter financial results for 2020.

Jazz Pharmaceuticals plc announced that the company will webcast its corporate presentations at the following virtual investor conferences

Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, reported financial results for its fiscal second quarter ended March 31, 2020.

ERYTECH Pharma (Nasdaq & Euronext: ERYP),a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update.

Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), today announced its results for the three-month period ended March 31, 2020.

SIWA Therapeutics, a Chicago-based, pre-clinical biopharmaceutical company, announced today that it is testing the ability of its humanized monoclonal antibody, SIWA 318H (the SIWA “mAb”) to directly target virally infected cells, including specifically, COVID-19.

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, announced a $390 million Series D financing round.

INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that it will host a conference call on May 14, 2020 at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2020.

Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported business highlights and financial results for the first quarter of 2020.